Company intelligence / Profile preview
Cinfa
- Ownership
- Private
- Employees
- ~2200
- Development stage
- Commercial
Overview
Cinfa has a broad commercial portfolio of over 1,370 presentations covering all major therapeutic areas. Its biosimilars arm developed B12019/pegfilgrastim biosimilar ("Pelmeg"), which has achieved positive clinical results and reached the market for neutropenia in oncology patients[1][6]. The company also leads the Spanish generics market and maintains a strong presence in prescription/non-prescription medicines as well as health/wellness products[3].
- Therapeutic areas
- OtherOncologyImmunologyHematology
- Modalities
- Small moleculeRecombinant proteinBiosimilarNutritional supplementMedical device
- Industry
- Pharma
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Cinfa.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cinfa.